{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hsia DS"],"funding":["NCATS NIH HHS","Centers for Disease Control and Prevention","NIDDK NIH HHS","National Institute of Diabetes and Digestive and Kidney Diseases","American Diabetes Association","National Institutes of Health","National Heart Lung and Blood Institute","NIGMS NIH HHS"],"pagination":["108692"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10923170"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["38(3)"],"pubmed_abstract":["Based on self-report in the GRADE diabetes study, cumulative incidence of retinopathy was low over 5 years (3.7 %; 184 of 4098 participants) and did not differ among the 4 treatment groups (glargine 4.0 %, glimepiride 3.2 %, liraglutide 3.7 %, sitagliptin 3.8 %). There were no differences in retinopathy with specific therapies in GRADE. Clinicaltrials.gov identifier: NCT01794143."],"journal":["Journal of diabetes and its complications"],"pubmed_title":["The incidence of retinopathy in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness study (GRADE)."],"pmcid":["PMC10923170"],"funding_grant_id":["UL1 TR002378","UM1 TR004528","UL1 TR002537","UL1 TR001425","UL1 TR002535","UL1 TR000439","UL1 TR001108","UL1 TR001449","UL1 TR001409","P30 DK020572","U01DK098246","P30 DK020541–44","U34-DK-088043","UL1 TR002243","2UL1TR001425","P30 DK092926","UL1 TR002489","UL1 TR002345","UL1 TR002548","P30 DK017047","U54 GM104940","UL1 TR000445","UL1 TR002529","U34 DK088043","P30 DK072476","U01 DK098246","P30 DK079626","P30 DK020541"],"pubmed_authors":["Kassem LS","Krause-Steinrauf H","GRADE Research Group","Younes N","Hsia DS"],"additional_accession":[]},"is_claimable":false,"name":"The incidence of retinopathy in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness study (GRADE).","description":"Based on self-report in the GRADE diabetes study, cumulative incidence of retinopathy was low over 5 years (3.7 %; 184 of 4098 participants) and did not differ among the 4 treatment groups (glargine 4.0 %, glimepiride 3.2 %, liraglutide 3.7 %, sitagliptin 3.8 %). There were no differences in retinopathy with specific therapies in GRADE. Clinicaltrials.gov identifier: NCT01794143.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-06-02T10:23:45.642Z","creation":"2025-04-07T07:47:23.164Z"},"accession":"S-EPMC10923170","cross_references":{"pubmed":["38354481"],"doi":["10.1016/j.jdiacomp.2024.108692"]}}